nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—glaucoma	0.28	0.678	CbGaD
Thalidomide—PTGS2—glaucoma	0.133	0.322	CbGaD
Thalidomide—CYP2E1—Pilocarpine—glaucoma	0.0523	0.184	CbGbCtD
Thalidomide—CYP2E1—Methazolamide—glaucoma	0.0354	0.125	CbGbCtD
Thalidomide—CYP1A1—Clonidine—glaucoma	0.0331	0.117	CbGbCtD
Thalidomide—CYP1A2—Betaxolol—glaucoma	0.027	0.095	CbGbCtD
Thalidomide—CYP2C19—Methazolamide—glaucoma	0.0222	0.078	CbGbCtD
Thalidomide—CYP2C9—Diclofenamide—glaucoma	0.0214	0.0754	CbGbCtD
Thalidomide—CYP2C9—Dorzolamide—glaucoma	0.0207	0.0728	CbGbCtD
Thalidomide—CYP3A5—Clonidine—glaucoma	0.0199	0.07	CbGbCtD
Thalidomide—CYP2C19—Timolol—glaucoma	0.0188	0.0664	CbGbCtD
Thalidomide—CYP2C9—Methazolamide—glaucoma	0.0184	0.0649	CbGbCtD
Thalidomide—CYP1A2—Clonidine—glaucoma	0.0148	0.0521	CbGbCtD
Thalidomide—FGFR2—cornea—glaucoma	0.00772	0.518	CbGeAlD
Thalidomide—Pomalidomide—TNF—glaucoma	0.0015	0.389	CrCbGaD
Thalidomide—NFKB1—eye—glaucoma	0.00127	0.085	CbGeAlD
Thalidomide—NFKB1—connective tissue—glaucoma	0.00122	0.0819	CbGeAlD
Thalidomide—CRBN—retina—glaucoma	0.00105	0.0706	CbGeAlD
Thalidomide—FGFR2—eye—glaucoma	0.000951	0.0638	CbGeAlD
Thalidomide—FGFR2—connective tissue—glaucoma	0.000917	0.0615	CbGeAlD
Thalidomide—Menadione—MTHFR—glaucoma	0.000871	0.227	CrCbGaD
Thalidomide—Lenalidomide—PTGS2—glaucoma	0.000765	0.199	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—glaucoma	0.000711	0.185	CrCbGaD
Thalidomide—PTGS1—endothelium—glaucoma	0.000616	0.0414	CbGeAlD
Thalidomide—PTGS2—endothelium—glaucoma	0.000589	0.0395	CbGeAlD
Thalidomide—PTGS1—connective tissue—glaucoma	0.000291	0.0196	CbGeAlD
Thalidomide—PTGS2—connective tissue—glaucoma	0.000279	0.0187	CbGeAlD
Thalidomide—Alopecia—Betaxolol—glaucoma	7.8e-05	0.000415	CcSEcCtD
Thalidomide—Palpitations—Clonidine—glaucoma	7.8e-05	0.000415	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Pilocarpine—glaucoma	7.79e-05	0.000415	CcSEcCtD
Thalidomide—Gastrointestinal pain—Travoprost—glaucoma	7.77e-05	0.000414	CcSEcCtD
Thalidomide—Loss of consciousness—Clonidine—glaucoma	7.76e-05	0.000413	CcSEcCtD
Thalidomide—Feeling abnormal—Brinzolamide—glaucoma	7.73e-05	0.000412	CcSEcCtD
Thalidomide—Mental disorder—Betaxolol—glaucoma	7.73e-05	0.000412	CcSEcCtD
Thalidomide—Pain—Pilocarpine—glaucoma	7.71e-05	0.000411	CcSEcCtD
Thalidomide—Constipation—Pilocarpine—glaucoma	7.71e-05	0.000411	CcSEcCtD
Thalidomide—Cough—Clonidine—glaucoma	7.7e-05	0.00041	CcSEcCtD
Thalidomide—Sweating—Timolol—glaucoma	7.7e-05	0.00041	CcSEcCtD
Thalidomide—Dizziness—Apraclonidine—glaucoma	7.7e-05	0.00041	CcSEcCtD
Thalidomide—Malnutrition—Betaxolol—glaucoma	7.68e-05	0.000409	CcSEcCtD
Thalidomide—Urticaria—Dorzolamide—glaucoma	7.58e-05	0.000404	CcSEcCtD
Thalidomide—Epistaxis—Timolol—glaucoma	7.58e-05	0.000403	CcSEcCtD
Thalidomide—Abdominal pain—Dorzolamide—glaucoma	7.55e-05	0.000402	CcSEcCtD
Thalidomide—Body temperature increased—Dorzolamide—glaucoma	7.55e-05	0.000402	CcSEcCtD
Thalidomide—Tension—Betaxolol—glaucoma	7.54e-05	0.000401	CcSEcCtD
Thalidomide—Sinusitis—Timolol—glaucoma	7.54e-05	0.000401	CcSEcCtD
Thalidomide—Dysgeusia—Betaxolol—glaucoma	7.52e-05	0.000401	CcSEcCtD
Thalidomide—Arthralgia—Clonidine—glaucoma	7.51e-05	0.0004	CcSEcCtD
Thalidomide—Chest pain—Clonidine—glaucoma	7.51e-05	0.0004	CcSEcCtD
Thalidomide—Abdominal pain—Travoprost—glaucoma	7.51e-05	0.0004	CcSEcCtD
Thalidomide—Agranulocytosis—Timolol—glaucoma	7.5e-05	0.000399	CcSEcCtD
Thalidomide—Anxiety—Clonidine—glaucoma	7.49e-05	0.000399	CcSEcCtD
Thalidomide—Asthenia—Acetazolamide—glaucoma	7.47e-05	0.000398	CcSEcCtD
Thalidomide—Dizziness—Bimatoprost—glaucoma	7.46e-05	0.000397	CcSEcCtD
Thalidomide—Nervousness—Betaxolol—glaucoma	7.46e-05	0.000397	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	7.46e-05	0.000397	CcSEcCtD
Thalidomide—Urticaria—Brinzolamide—glaucoma	7.46e-05	0.000397	CcSEcCtD
Thalidomide—Feeling abnormal—Pilocarpine—glaucoma	7.43e-05	0.000396	CcSEcCtD
Thalidomide—Discomfort—Clonidine—glaucoma	7.42e-05	0.000395	CcSEcCtD
Thalidomide—Vomiting—Apraclonidine—glaucoma	7.4e-05	0.000394	CcSEcCtD
Thalidomide—Muscle spasms—Betaxolol—glaucoma	7.39e-05	0.000393	CcSEcCtD
Thalidomide—Gastrointestinal pain—Pilocarpine—glaucoma	7.38e-05	0.000393	CcSEcCtD
Thalidomide—Hypersensitivity—Brimonidine—glaucoma	7.36e-05	0.000392	CcSEcCtD
Thalidomide—Dry mouth—Clonidine—glaucoma	7.35e-05	0.000391	CcSEcCtD
Thalidomide—Bradycardia—Timolol—glaucoma	7.34e-05	0.000391	CcSEcCtD
Thalidomide—Dermatitis—Apraclonidine—glaucoma	7.33e-05	0.000391	CcSEcCtD
Thalidomide—Headache—Apraclonidine—glaucoma	7.29e-05	0.000388	CcSEcCtD
Thalidomide—Confusional state—Clonidine—glaucoma	7.26e-05	0.000387	CcSEcCtD
Thalidomide—Vision blurred—Betaxolol—glaucoma	7.24e-05	0.000386	CcSEcCtD
Thalidomide—Rhinitis—Timolol—glaucoma	7.23e-05	0.000385	CcSEcCtD
Thalidomide—Oedema—Clonidine—glaucoma	7.2e-05	0.000384	CcSEcCtD
Thalidomide—Tremor—Betaxolol—glaucoma	7.2e-05	0.000383	CcSEcCtD
Thalidomide—Asthenia—Brimonidine—glaucoma	7.17e-05	0.000382	CcSEcCtD
Thalidomide—Infection—Clonidine—glaucoma	7.16e-05	0.000381	CcSEcCtD
Thalidomide—Abdominal pain—Pilocarpine—glaucoma	7.13e-05	0.00038	CcSEcCtD
Thalidomide—Body temperature increased—Pilocarpine—glaucoma	7.13e-05	0.00038	CcSEcCtD
Thalidomide—Ill-defined disorder—Betaxolol—glaucoma	7.13e-05	0.00038	CcSEcCtD
Thalidomide—Diarrhoea—Acetazolamide—glaucoma	7.13e-05	0.000379	CcSEcCtD
Thalidomide—Rash—Bimatoprost—glaucoma	7.12e-05	0.000379	CcSEcCtD
Thalidomide—Dermatitis—Bimatoprost—glaucoma	7.11e-05	0.000379	CcSEcCtD
Thalidomide—Oedema peripheral—Timolol—glaucoma	7.1e-05	0.000378	CcSEcCtD
Thalidomide—Anaemia—Betaxolol—glaucoma	7.1e-05	0.000378	CcSEcCtD
Thalidomide—Shock—Clonidine—glaucoma	7.09e-05	0.000377	CcSEcCtD
Thalidomide—Pruritus—Brimonidine—glaucoma	7.07e-05	0.000377	CcSEcCtD
Thalidomide—Headache—Bimatoprost—glaucoma	7.07e-05	0.000377	CcSEcCtD
Thalidomide—Nervous system disorder—Clonidine—glaucoma	7.06e-05	0.000376	CcSEcCtD
Thalidomide—Thrombocytopenia—Clonidine—glaucoma	7.05e-05	0.000376	CcSEcCtD
Thalidomide—Hypersensitivity—Dorzolamide—glaucoma	7.03e-05	0.000374	CcSEcCtD
Thalidomide—Tachycardia—Clonidine—glaucoma	7.03e-05	0.000374	CcSEcCtD
Thalidomide—Hypersensitivity—Travoprost—glaucoma	7e-05	0.000373	CcSEcCtD
Thalidomide—Skin disorder—Clonidine—glaucoma	7e-05	0.000373	CcSEcCtD
Thalidomide—Hyperhidrosis—Clonidine—glaucoma	6.96e-05	0.000371	CcSEcCtD
Thalidomide—Visual impairment—Timolol—glaucoma	6.95e-05	0.00037	CcSEcCtD
Thalidomide—Malaise—Betaxolol—glaucoma	6.93e-05	0.000369	CcSEcCtD
Thalidomide—Nausea—Apraclonidine—glaucoma	6.92e-05	0.000368	CcSEcCtD
Thalidomide—Hypersensitivity—Brinzolamide—glaucoma	6.91e-05	0.000368	CcSEcCtD
Thalidomide—Vertigo—Betaxolol—glaucoma	6.9e-05	0.000368	CcSEcCtD
Thalidomide—Syncope—Betaxolol—glaucoma	6.89e-05	0.000367	CcSEcCtD
Thalidomide—Dizziness—Acetazolamide—glaucoma	6.89e-05	0.000367	CcSEcCtD
Thalidomide—Anorexia—Clonidine—glaucoma	6.87e-05	0.000366	CcSEcCtD
Thalidomide—Asthenia—Dorzolamide—glaucoma	6.85e-05	0.000365	CcSEcCtD
Thalidomide—Asthenia—Travoprost—glaucoma	6.82e-05	0.000363	CcSEcCtD
Thalidomide—Palpitations—Betaxolol—glaucoma	6.79e-05	0.000362	CcSEcCtD
Thalidomide—Pruritus—Dorzolamide—glaucoma	6.75e-05	0.00036	CcSEcCtD
Thalidomide—Loss of consciousness—Betaxolol—glaucoma	6.75e-05	0.00036	CcSEcCtD
Thalidomide—Eye disorder—Timolol—glaucoma	6.74e-05	0.000359	CcSEcCtD
Thalidomide—Asthenia—Brinzolamide—glaucoma	6.73e-05	0.000359	CcSEcCtD
Thalidomide—Hypotension—Clonidine—glaucoma	6.73e-05	0.000358	CcSEcCtD
Thalidomide—Pruritus—Travoprost—glaucoma	6.72e-05	0.000358	CcSEcCtD
Thalidomide—Tinnitus—Timolol—glaucoma	6.72e-05	0.000358	CcSEcCtD
Thalidomide—Cough—Betaxolol—glaucoma	6.71e-05	0.000357	CcSEcCtD
Thalidomide—Nausea—Bimatoprost—glaucoma	6.7e-05	0.000357	CcSEcCtD
Thalidomide—Cardiac disorder—Timolol—glaucoma	6.69e-05	0.000356	CcSEcCtD
Thalidomide—Hypersensitivity—Pilocarpine—glaucoma	6.65e-05	0.000354	CcSEcCtD
Thalidomide—Pruritus—Brinzolamide—glaucoma	6.64e-05	0.000354	CcSEcCtD
Thalidomide—Vomiting—Acetazolamide—glaucoma	6.62e-05	0.000353	CcSEcCtD
Thalidomide—Dizziness—Brimonidine—glaucoma	6.61e-05	0.000352	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Clonidine—glaucoma	6.56e-05	0.000349	CcSEcCtD
Thalidomide—Angiopathy—Timolol—glaucoma	6.54e-05	0.000348	CcSEcCtD
Thalidomide—Arthralgia—Betaxolol—glaucoma	6.54e-05	0.000348	CcSEcCtD
Thalidomide—Myalgia—Betaxolol—glaucoma	6.54e-05	0.000348	CcSEcCtD
Thalidomide—Chest pain—Betaxolol—glaucoma	6.54e-05	0.000348	CcSEcCtD
Thalidomide—Diarrhoea—Dorzolamide—glaucoma	6.53e-05	0.000348	CcSEcCtD
Thalidomide—Headache—Acetazolamide—glaucoma	6.52e-05	0.000347	CcSEcCtD
Thalidomide—Anxiety—Betaxolol—glaucoma	6.52e-05	0.000347	CcSEcCtD
Thalidomide—Insomnia—Clonidine—glaucoma	6.51e-05	0.000347	CcSEcCtD
Thalidomide—Immune system disorder—Timolol—glaucoma	6.51e-05	0.000347	CcSEcCtD
Thalidomide—Diarrhoea—Travoprost—glaucoma	6.5e-05	0.000346	CcSEcCtD
Thalidomide—Mediastinal disorder—Timolol—glaucoma	6.5e-05	0.000346	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	6.5e-05	0.000346	CcSEcCtD
Thalidomide—Asthenia—Pilocarpine—glaucoma	6.47e-05	0.000345	CcSEcCtD
Thalidomide—Paraesthesia—Clonidine—glaucoma	6.47e-05	0.000344	CcSEcCtD
Thalidomide—Discomfort—Betaxolol—glaucoma	6.46e-05	0.000344	CcSEcCtD
Thalidomide—Arrhythmia—Timolol—glaucoma	6.44e-05	0.000343	CcSEcCtD
Thalidomide—Dyspnoea—Clonidine—glaucoma	6.42e-05	0.000342	CcSEcCtD
Thalidomide—Diarrhoea—Brinzolamide—glaucoma	6.42e-05	0.000342	CcSEcCtD
Thalidomide—Somnolence—Clonidine—glaucoma	6.4e-05	0.000341	CcSEcCtD
Thalidomide—Dry mouth—Betaxolol—glaucoma	6.4e-05	0.000341	CcSEcCtD
Thalidomide—Pruritus—Pilocarpine—glaucoma	6.38e-05	0.00034	CcSEcCtD
Thalidomide—Alopecia—Timolol—glaucoma	6.37e-05	0.000339	CcSEcCtD
Thalidomide—Confusional state—Betaxolol—glaucoma	6.32e-05	0.000337	CcSEcCtD
Thalidomide—Mental disorder—Timolol—glaucoma	6.32e-05	0.000336	CcSEcCtD
Thalidomide—Dizziness—Dorzolamide—glaucoma	6.31e-05	0.000336	CcSEcCtD
Thalidomide—Rash—Brimonidine—glaucoma	6.3e-05	0.000336	CcSEcCtD
Thalidomide—Dermatitis—Brimonidine—glaucoma	6.3e-05	0.000335	CcSEcCtD
Thalidomide—Dizziness—Travoprost—glaucoma	6.29e-05	0.000335	CcSEcCtD
Thalidomide—Malnutrition—Timolol—glaucoma	6.28e-05	0.000334	CcSEcCtD
Thalidomide—Oedema—Betaxolol—glaucoma	6.27e-05	0.000334	CcSEcCtD
Thalidomide—Headache—Brimonidine—glaucoma	6.26e-05	0.000333	CcSEcCtD
Thalidomide—Decreased appetite—Clonidine—glaucoma	6.26e-05	0.000333	CcSEcCtD
Thalidomide—Infection—Betaxolol—glaucoma	6.23e-05	0.000332	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Clonidine—glaucoma	6.22e-05	0.000331	CcSEcCtD
Thalidomide—Fatigue—Clonidine—glaucoma	6.21e-05	0.000331	CcSEcCtD
Thalidomide—Dizziness—Brinzolamide—glaucoma	6.21e-05	0.00033	CcSEcCtD
Thalidomide—Nausea—Acetazolamide—glaucoma	6.19e-05	0.000329	CcSEcCtD
Thalidomide—Diarrhoea—Pilocarpine—glaucoma	6.17e-05	0.000329	CcSEcCtD
Thalidomide—Shock—Betaxolol—glaucoma	6.17e-05	0.000329	CcSEcCtD
Thalidomide—Tension—Timolol—glaucoma	6.16e-05	0.000328	CcSEcCtD
Thalidomide—Constipation—Clonidine—glaucoma	6.16e-05	0.000328	CcSEcCtD
Thalidomide—Pain—Clonidine—glaucoma	6.16e-05	0.000328	CcSEcCtD
Thalidomide—Nervous system disorder—Betaxolol—glaucoma	6.15e-05	0.000327	CcSEcCtD
Thalidomide—Dysgeusia—Timolol—glaucoma	6.15e-05	0.000327	CcSEcCtD
Thalidomide—Thrombocytopenia—Betaxolol—glaucoma	6.14e-05	0.000327	CcSEcCtD
Thalidomide—Tachycardia—Betaxolol—glaucoma	6.12e-05	0.000326	CcSEcCtD
Thalidomide—Nervousness—Timolol—glaucoma	6.1e-05	0.000325	CcSEcCtD
Thalidomide—Skin disorder—Betaxolol—glaucoma	6.09e-05	0.000324	CcSEcCtD
Thalidomide—Vomiting—Dorzolamide—glaucoma	6.07e-05	0.000323	CcSEcCtD
Thalidomide—Hyperhidrosis—Betaxolol—glaucoma	6.06e-05	0.000323	CcSEcCtD
Thalidomide—Rash—Dorzolamide—glaucoma	6.02e-05	0.00032	CcSEcCtD
Thalidomide—Dermatitis—Dorzolamide—glaucoma	6.01e-05	0.00032	CcSEcCtD
Thalidomide—Rash—Travoprost—glaucoma	5.99e-05	0.000319	CcSEcCtD
Thalidomide—Dermatitis—Travoprost—glaucoma	5.99e-05	0.000319	CcSEcCtD
Thalidomide—Headache—Dorzolamide—glaucoma	5.98e-05	0.000318	CcSEcCtD
Thalidomide—Anorexia—Betaxolol—glaucoma	5.98e-05	0.000318	CcSEcCtD
Thalidomide—Vomiting—Brinzolamide—glaucoma	5.97e-05	0.000318	CcSEcCtD
Thalidomide—Dizziness—Pilocarpine—glaucoma	5.96e-05	0.000318	CcSEcCtD
Thalidomide—Headache—Travoprost—glaucoma	5.95e-05	0.000317	CcSEcCtD
Thalidomide—Nausea—Brimonidine—glaucoma	5.94e-05	0.000316	CcSEcCtD
Thalidomide—Feeling abnormal—Clonidine—glaucoma	5.94e-05	0.000316	CcSEcCtD
Thalidomide—Rash—Brinzolamide—glaucoma	5.92e-05	0.000315	CcSEcCtD
Thalidomide—Vision blurred—Timolol—glaucoma	5.92e-05	0.000315	CcSEcCtD
Thalidomide—Dermatitis—Brinzolamide—glaucoma	5.91e-05	0.000315	CcSEcCtD
Thalidomide—Gastrointestinal pain—Clonidine—glaucoma	5.89e-05	0.000314	CcSEcCtD
Thalidomide—Headache—Brinzolamide—glaucoma	5.88e-05	0.000313	CcSEcCtD
Thalidomide—Hypotension—Betaxolol—glaucoma	5.86e-05	0.000312	CcSEcCtD
Thalidomide—Angioedema—Timolol—glaucoma	5.74e-05	0.000305	CcSEcCtD
Thalidomide—Vomiting—Pilocarpine—glaucoma	5.73e-05	0.000305	CcSEcCtD
Thalidomide—Urticaria—Clonidine—glaucoma	5.72e-05	0.000305	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betaxolol—glaucoma	5.71e-05	0.000304	CcSEcCtD
Thalidomide—Abdominal pain—Clonidine—glaucoma	5.69e-05	0.000303	CcSEcCtD
Thalidomide—Body temperature increased—Clonidine—glaucoma	5.69e-05	0.000303	CcSEcCtD
Thalidomide—Rash—Pilocarpine—glaucoma	5.69e-05	0.000303	CcSEcCtD
Thalidomide—Dermatitis—Pilocarpine—glaucoma	5.68e-05	0.000303	CcSEcCtD
Thalidomide—Insomnia—Betaxolol—glaucoma	5.67e-05	0.000302	CcSEcCtD
Thalidomide—Nausea—Dorzolamide—glaucoma	5.67e-05	0.000302	CcSEcCtD
Thalidomide—Headache—Pilocarpine—glaucoma	5.65e-05	0.000301	CcSEcCtD
Thalidomide—Nausea—Travoprost—glaucoma	5.65e-05	0.000301	CcSEcCtD
Thalidomide—Vertigo—Timolol—glaucoma	5.64e-05	0.0003	CcSEcCtD
Thalidomide—Paraesthesia—Betaxolol—glaucoma	5.63e-05	0.0003	CcSEcCtD
Thalidomide—Syncope—Timolol—glaucoma	5.63e-05	0.0003	CcSEcCtD
Thalidomide—Dyspnoea—Betaxolol—glaucoma	5.59e-05	0.000298	CcSEcCtD
Thalidomide—Nausea—Brinzolamide—glaucoma	5.57e-05	0.000297	CcSEcCtD
Thalidomide—Palpitations—Timolol—glaucoma	5.55e-05	0.000295	CcSEcCtD
Thalidomide—Dyspepsia—Betaxolol—glaucoma	5.52e-05	0.000294	CcSEcCtD
Thalidomide—Loss of consciousness—Timolol—glaucoma	5.52e-05	0.000294	CcSEcCtD
Thalidomide—Cough—Timolol—glaucoma	5.48e-05	0.000292	CcSEcCtD
Thalidomide—Decreased appetite—Betaxolol—glaucoma	5.45e-05	0.00029	CcSEcCtD
Thalidomide—Hypertension—Timolol—glaucoma	5.42e-05	0.000289	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betaxolol—glaucoma	5.41e-05	0.000288	CcSEcCtD
Thalidomide—Fatigue—Betaxolol—glaucoma	5.41e-05	0.000288	CcSEcCtD
Thalidomide—Pain—Betaxolol—glaucoma	5.36e-05	0.000286	CcSEcCtD
Thalidomide—Constipation—Betaxolol—glaucoma	5.36e-05	0.000286	CcSEcCtD
Thalidomide—Nausea—Pilocarpine—glaucoma	5.36e-05	0.000285	CcSEcCtD
Thalidomide—Arthralgia—Timolol—glaucoma	5.34e-05	0.000285	CcSEcCtD
Thalidomide—Chest pain—Timolol—glaucoma	5.34e-05	0.000285	CcSEcCtD
Thalidomide—Myalgia—Timolol—glaucoma	5.34e-05	0.000285	CcSEcCtD
Thalidomide—Anxiety—Timolol—glaucoma	5.33e-05	0.000284	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	5.31e-05	0.000283	CcSEcCtD
Thalidomide—Hypersensitivity—Clonidine—glaucoma	5.31e-05	0.000283	CcSEcCtD
Thalidomide—Discomfort—Timolol—glaucoma	5.28e-05	0.000281	CcSEcCtD
Thalidomide—Dry mouth—Timolol—glaucoma	5.23e-05	0.000278	CcSEcCtD
Thalidomide—Asthenia—Clonidine—glaucoma	5.17e-05	0.000275	CcSEcCtD
Thalidomide—Feeling abnormal—Betaxolol—glaucoma	5.17e-05	0.000275	CcSEcCtD
Thalidomide—Confusional state—Timolol—glaucoma	5.17e-05	0.000275	CcSEcCtD
Thalidomide—Oedema—Timolol—glaucoma	5.12e-05	0.000273	CcSEcCtD
Thalidomide—Pruritus—Clonidine—glaucoma	5.1e-05	0.000271	CcSEcCtD
Thalidomide—Infection—Timolol—glaucoma	5.09e-05	0.000271	CcSEcCtD
Thalidomide—Shock—Timolol—glaucoma	5.04e-05	0.000268	CcSEcCtD
Thalidomide—Nervous system disorder—Timolol—glaucoma	5.02e-05	0.000268	CcSEcCtD
Thalidomide—Urticaria—Betaxolol—glaucoma	4.98e-05	0.000265	CcSEcCtD
Thalidomide—Skin disorder—Timolol—glaucoma	4.98e-05	0.000265	CcSEcCtD
Thalidomide—Body temperature increased—Betaxolol—glaucoma	4.96e-05	0.000264	CcSEcCtD
Thalidomide—Hyperhidrosis—Timolol—glaucoma	4.95e-05	0.000264	CcSEcCtD
Thalidomide—Diarrhoea—Clonidine—glaucoma	4.93e-05	0.000262	CcSEcCtD
Thalidomide—Anorexia—Timolol—glaucoma	4.88e-05	0.00026	CcSEcCtD
Thalidomide—Hypotension—Timolol—glaucoma	4.79e-05	0.000255	CcSEcCtD
Thalidomide—Dizziness—Clonidine—glaucoma	4.76e-05	0.000254	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Timolol—glaucoma	4.67e-05	0.000249	CcSEcCtD
Thalidomide—Insomnia—Timolol—glaucoma	4.63e-05	0.000247	CcSEcCtD
Thalidomide—Hypersensitivity—Betaxolol—glaucoma	4.62e-05	0.000246	CcSEcCtD
Thalidomide—Paraesthesia—Timolol—glaucoma	4.6e-05	0.000245	CcSEcCtD
Thalidomide—Vomiting—Clonidine—glaucoma	4.58e-05	0.000244	CcSEcCtD
Thalidomide—Dyspnoea—Timolol—glaucoma	4.57e-05	0.000243	CcSEcCtD
Thalidomide—Somnolence—Timolol—glaucoma	4.55e-05	0.000243	CcSEcCtD
Thalidomide—Rash—Clonidine—glaucoma	4.54e-05	0.000242	CcSEcCtD
Thalidomide—Dermatitis—Clonidine—glaucoma	4.54e-05	0.000242	CcSEcCtD
Thalidomide—Headache—Clonidine—glaucoma	4.51e-05	0.00024	CcSEcCtD
Thalidomide—Dyspepsia—Timolol—glaucoma	4.51e-05	0.00024	CcSEcCtD
Thalidomide—Asthenia—Betaxolol—glaucoma	4.5e-05	0.00024	CcSEcCtD
Thalidomide—Decreased appetite—Timolol—glaucoma	4.45e-05	0.000237	CcSEcCtD
Thalidomide—Pruritus—Betaxolol—glaucoma	4.44e-05	0.000236	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Timolol—glaucoma	4.42e-05	0.000236	CcSEcCtD
Thalidomide—Fatigue—Timolol—glaucoma	4.42e-05	0.000235	CcSEcCtD
Thalidomide—Pain—Timolol—glaucoma	4.38e-05	0.000233	CcSEcCtD
Thalidomide—Diarrhoea—Betaxolol—glaucoma	4.29e-05	0.000228	CcSEcCtD
Thalidomide—Nausea—Clonidine—glaucoma	4.28e-05	0.000228	CcSEcCtD
Thalidomide—Feeling abnormal—Timolol—glaucoma	4.22e-05	0.000225	CcSEcCtD
Thalidomide—Gastrointestinal pain—Timolol—glaucoma	4.19e-05	0.000223	CcSEcCtD
Thalidomide—Dizziness—Betaxolol—glaucoma	4.15e-05	0.000221	CcSEcCtD
Thalidomide—Urticaria—Timolol—glaucoma	4.07e-05	0.000217	CcSEcCtD
Thalidomide—Abdominal pain—Timolol—glaucoma	4.05e-05	0.000216	CcSEcCtD
Thalidomide—Body temperature increased—Timolol—glaucoma	4.05e-05	0.000216	CcSEcCtD
Thalidomide—Vomiting—Betaxolol—glaucoma	3.99e-05	0.000212	CcSEcCtD
Thalidomide—Rash—Betaxolol—glaucoma	3.95e-05	0.000211	CcSEcCtD
Thalidomide—Dermatitis—Betaxolol—glaucoma	3.95e-05	0.00021	CcSEcCtD
Thalidomide—Headache—Betaxolol—glaucoma	3.93e-05	0.000209	CcSEcCtD
Thalidomide—Hypersensitivity—Timolol—glaucoma	3.77e-05	0.000201	CcSEcCtD
Thalidomide—Nausea—Betaxolol—glaucoma	3.72e-05	0.000198	CcSEcCtD
Thalidomide—Asthenia—Timolol—glaucoma	3.68e-05	0.000196	CcSEcCtD
Thalidomide—Pruritus—Timolol—glaucoma	3.62e-05	0.000193	CcSEcCtD
Thalidomide—Diarrhoea—Timolol—glaucoma	3.51e-05	0.000187	CcSEcCtD
Thalidomide—Dizziness—Timolol—glaucoma	3.39e-05	0.00018	CcSEcCtD
Thalidomide—Vomiting—Timolol—glaucoma	3.26e-05	0.000173	CcSEcCtD
Thalidomide—Rash—Timolol—glaucoma	3.23e-05	0.000172	CcSEcCtD
Thalidomide—Dermatitis—Timolol—glaucoma	3.23e-05	0.000172	CcSEcCtD
Thalidomide—Headache—Timolol—glaucoma	3.21e-05	0.000171	CcSEcCtD
Thalidomide—Nausea—Timolol—glaucoma	3.04e-05	0.000162	CcSEcCtD
Thalidomide—CYP2C19—Metapathway biotransformation—GSTM1—glaucoma	2.93e-05	0.000302	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—CDKN1B—glaucoma	2.93e-05	0.000302	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C3—glaucoma	2.91e-05	0.000301	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP1B1—glaucoma	2.9e-05	0.000299	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	2.88e-05	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NCK2—glaucoma	2.86e-05	0.000295	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP1B1—glaucoma	2.86e-05	0.000295	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RPTOR—glaucoma	2.81e-05	0.000289	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—C3—glaucoma	2.8e-05	0.000289	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—BCL2L1—glaucoma	2.79e-05	0.000288	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CA1—glaucoma	2.77e-05	0.000286	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C3—glaucoma	2.76e-05	0.000285	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—glaucoma	2.74e-05	0.000282	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—glaucoma	2.74e-05	0.000282	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—glaucoma	2.74e-05	0.000282	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NCK2—glaucoma	2.72e-05	0.00028	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—GSTM1—glaucoma	2.71e-05	0.000279	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	2.71e-05	0.000279	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	2.7e-05	0.000279	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CTSA—glaucoma	2.68e-05	0.000277	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.68e-05	0.000276	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—GSTM1—glaucoma	2.67e-05	0.000276	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	2.66e-05	0.000275	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—C3—glaucoma	2.65e-05	0.000274	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—BCL2L1—glaucoma	2.65e-05	0.000273	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR1OP—glaucoma	2.63e-05	0.000271	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HEYL—glaucoma	2.63e-05	0.000271	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NARFL—glaucoma	2.55e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA5A—glaucoma	2.55e-05	0.000263	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CA2—glaucoma	2.53e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	2.53e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—glaucoma	2.53e-05	0.000261	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—BAD—glaucoma	2.53e-05	0.000261	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	2.48e-05	0.000255	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	2.48e-05	0.000255	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—glaucoma	2.46e-05	0.000253	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HDAC9—glaucoma	2.43e-05	0.000251	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—BAD—glaucoma	2.43e-05	0.00025	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—glaucoma	2.41e-05	0.000249	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—BAD—glaucoma	2.4e-05	0.000247	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GSTM1—glaucoma	2.32e-05	0.000239	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HDAC9—glaucoma	2.31e-05	0.000238	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—BAD—glaucoma	2.3e-05	0.000238	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—GSTM1—glaucoma	2.28e-05	0.000235	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—glaucoma	2.26e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CA1—glaucoma	2.2e-05	0.000227	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CTSA—glaucoma	2.13e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—glaucoma	2.1e-05	0.000217	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CA1—glaucoma	2.07e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—glaucoma	2.07e-05	0.000213	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CA1—glaucoma	2.07e-05	0.000213	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.04e-05	0.000211	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CA2—glaucoma	2.01e-05	0.000207	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	2.01e-05	0.000207	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CTSA—glaucoma	2e-05	0.000207	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CTSA—glaucoma	2e-05	0.000206	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.97e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.97e-05	0.000203	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CA1—glaucoma	1.95e-05	0.000201	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1A—glaucoma	1.93e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMO—glaucoma	1.91e-05	0.000196	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CA2—glaucoma	1.89e-05	0.000195	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CTSA—glaucoma	1.89e-05	0.000195	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CA2—glaucoma	1.89e-05	0.000195	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—glaucoma	1.87e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—glaucoma	1.86e-05	0.000191	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—glaucoma	1.85e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1A—glaucoma	1.83e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMO—glaucoma	1.81e-05	0.000186	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CA2—glaucoma	1.78e-05	0.000184	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TXN—glaucoma	1.78e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN2B—glaucoma	1.77e-05	0.000183	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDKN1B—glaucoma	1.76e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.74e-05	0.00018	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.74e-05	0.00018	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NTRK2—glaucoma	1.74e-05	0.00018	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C3—glaucoma	1.7e-05	0.000175	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDKN1B—glaucoma	1.69e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.67e-05	0.000172	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDKN1B—glaucoma	1.67e-05	0.000172	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—glaucoma	1.66e-05	0.000171	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NTRK2—glaucoma	1.65e-05	0.000171	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HDAC9—glaucoma	1.64e-05	0.000169	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.63e-05	0.000168	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2L1—glaucoma	1.62e-05	0.000168	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.61e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C3—glaucoma	1.61e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDKN1B—glaucoma	1.6e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CA1—glaucoma	1.6e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CTSA—glaucoma	1.55e-05	0.000159	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2L1—glaucoma	1.54e-05	0.000159	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NGFR—glaucoma	1.5e-05	0.000154	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTHFR—glaucoma	1.49e-05	0.000153	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BAD—glaucoma	1.47e-05	0.000152	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CA2—glaucoma	1.46e-05	0.000151	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CA1—glaucoma	1.46e-05	0.00015	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.43e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.43e-05	0.000147	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.43e-05	0.000147	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—glaucoma	1.42e-05	0.000147	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NTRK1—glaucoma	1.42e-05	0.000146	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NGFR—glaucoma	1.42e-05	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TXN—glaucoma	1.42e-05	0.000146	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTSA—glaucoma	1.41e-05	0.000145	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—glaucoma	1.41e-05	0.000145	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BAD—glaucoma	1.4e-05	0.000144	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—glaucoma	1.38e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTT1—glaucoma	1.38e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CAV1—glaucoma	1.37e-05	0.000141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NTRK1—glaucoma	1.35e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TXN—glaucoma	1.33e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CA2—glaucoma	1.33e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TXN—glaucoma	1.33e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN2B—glaucoma	1.31e-05	0.000135	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.3e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.3e-05	0.000134	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.29e-05	0.000133	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BAD—glaucoma	1.29e-05	0.000133	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.28e-05	0.000132	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—glaucoma	1.26e-05	0.00013	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.26e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TXN—glaucoma	1.26e-05	0.00013	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EDN1—glaucoma	1.26e-05	0.00013	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA1—glaucoma	1.24e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN2B—glaucoma	1.24e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTSA—glaucoma	1.2e-05	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EDN1—glaucoma	1.19e-05	0.000123	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NGF—glaucoma	1.15e-05	0.000119	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.15e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA2—glaucoma	1.14e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.14e-05	0.000117	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.12e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.11e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.11e-05	0.000115	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCA1—glaucoma	1.1e-05	0.000114	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1B1—glaucoma	1.1e-05	0.000114	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTT1—glaucoma	1.1e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C3—glaucoma	1.1e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NGF—glaucoma	1.1e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C3—glaucoma	1.04e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—glaucoma	1.04e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTT1—glaucoma	1.03e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTT1—glaucoma	1.03e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TXN—glaucoma	1.03e-05	0.000106	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1B—glaucoma	1.03e-05	0.000106	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—glaucoma	1.02e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CAV1—glaucoma	1.01e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTT1—glaucoma	9.75e-06	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1B—glaucoma	9.73e-06	0.0001	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—glaucoma	9.69e-06	0.0001	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FN1—glaucoma	9.63e-06	9.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CAV1—glaucoma	9.6e-06	9.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BAD—glaucoma	9.52e-06	9.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—glaucoma	9.48e-06	9.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	9.39e-06	9.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TXN—glaucoma	9.38e-06	9.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	9.3e-06	9.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FN1—glaucoma	9.14e-06	9.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BAD—glaucoma	9.03e-06	9.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1B—glaucoma	8.98e-06	9.26e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—glaucoma	8.81e-06	9.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN2B—glaucoma	8.81e-06	9.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCA1—glaucoma	8.75e-06	9.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1B1—glaucoma	8.75e-06	9.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.56e-06	8.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.48e-06	8.75e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1B1—glaucoma	8.24e-06	8.5e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCA1—glaucoma	8.24e-06	8.5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCA1—glaucoma	8.22e-06	8.48e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1B1—glaucoma	8.22e-06	8.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TXN—glaucoma	8.02e-06	8.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—glaucoma	7.98e-06	8.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	7.86e-06	8.11e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—glaucoma	7.79e-06	8.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCA1—glaucoma	7.77e-06	8.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP1B1—glaucoma	7.77e-06	8.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—glaucoma	7.65e-06	7.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—glaucoma	7.38e-06	7.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	7.31e-06	7.54e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—glaucoma	7.27e-06	7.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—glaucoma	7.26e-06	7.49e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—glaucoma	7.25e-06	7.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	7.25e-06	7.47e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAV1—glaucoma	7.18e-06	7.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—glaucoma	7e-06	7.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—glaucoma	6.87e-06	7.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CAV1—glaucoma	6.81e-06	7.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—glaucoma	6.63e-06	6.84e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—glaucoma	6.59e-06	6.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—glaucoma	6.57e-06	6.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.43e-06	6.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BAD—glaucoma	6.41e-06	6.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1B1—glaucoma	6.36e-06	6.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—glaucoma	6.36e-06	6.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—glaucoma	6.29e-06	6.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—glaucoma	6.22e-06	6.41e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—glaucoma	6.21e-06	6.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—glaucoma	6.18e-06	6.38e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—glaucoma	6.14e-06	6.33e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.87e-06	6.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—glaucoma	5.83e-06	6.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—glaucoma	5.82e-06	6e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—glaucoma	5.81e-06	5.99e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—glaucoma	5.8e-06	5.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1B1—glaucoma	5.8e-06	5.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—glaucoma	5.76e-06	5.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—glaucoma	5.7e-06	5.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—glaucoma	5.51e-06	5.69e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—glaucoma	5.49e-06	5.66e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—glaucoma	5.43e-06	5.6e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—glaucoma	5.42e-06	5.59e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—glaucoma	5.41e-06	5.58e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—glaucoma	5.37e-06	5.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—glaucoma	5.36e-06	5.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—glaucoma	5.23e-06	5.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—glaucoma	5.15e-06	5.31e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—glaucoma	5.11e-06	5.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—glaucoma	5.08e-06	5.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—glaucoma	5.06e-06	5.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.01e-06	5.17e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—glaucoma	4.97e-06	5.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—glaucoma	4.95e-06	5.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1B1—glaucoma	4.95e-06	5.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—glaucoma	4.63e-06	4.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—glaucoma	4.49e-06	4.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—glaucoma	4.46e-06	4.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—glaucoma	4.31e-06	4.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—glaucoma	4.18e-06	4.31e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—glaucoma	4.17e-06	4.3e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—glaucoma	4.14e-06	4.27e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—glaucoma	4.09e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—glaucoma	4.06e-06	4.19e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—glaucoma	4.05e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—glaucoma	3.96e-06	4.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—glaucoma	3.95e-06	4.08e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—glaucoma	3.83e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—glaucoma	3.81e-06	3.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—glaucoma	3.78e-06	3.9e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—glaucoma	3.71e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—glaucoma	3.71e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—glaucoma	3.5e-06	3.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—glaucoma	3.5e-06	3.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—glaucoma	3.26e-06	3.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—glaucoma	3.23e-06	3.33e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—glaucoma	3.13e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—glaucoma	2.86e-06	2.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—glaucoma	2.86e-06	2.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—glaucoma	2.61e-06	2.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—glaucoma	2.44e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—glaucoma	2.23e-06	2.3e-05	CbGpPWpGaD
